Clinical trial register · European Union · CTIS

Clinical Trials in France, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12788 total CTIS records — a stated recency window, not the full historical archive. Synced 08 Nov 2026, 03:17 UTC

2557

Shown in this register

most recently authorised

12,788

Total on CTIS

full historical archive

789

Phase III

within the shown window

Top member states

Spain 1074 France 933 Germany 893 Italy 777 Poland 614 Netherlands 544

Narrow the registerReset

Search within results

Phase

Lead sponsor

Member state

All 28 states

Trials with a site in France

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase I/II

A Long-term Follow-up Study in Male Participants with X-linked Myotubular Myopathy Treated with ASP2957

2025-524467-21-00X-linked myotubular myopathy

DrugASP2957

Astellas Gene Therapies Inc.

Musculoskeletal Diseases

France

06/11/2026

Phase I/II

Phase 1/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SAR447998 in adults with refractory Systemic Lupus Erythematosus or Rheumatoid Arthritis

2026-526117-28-00Systemic lupus erythematosus / Rheumatoid arthritis

Sanofi-Aventis Recherche & Developpement

Musculoskeletal Diseases

France

30/10/2026

Phase I/II

A Phase I/II multicenter, randomized, double-blind, dose-selecting trial to investigate the immunogenicity, reactogenicity and safety of an intradermally administered zoonotic influenza vaccine targeting H5N8 in different doses compared with intramuscular administration of the same vaccine in adults aged 40 to 80 years

2026-525756-28-00Avian Influenza

University Of Antwerp

Virus Diseases

Belgium, Netherlands, France, Germany

29/10/2026

Phase I/II

ORION-1: A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-023 as a single agent, and in combination with AVZO-021 and/or endocrine therapy in patients with advanced solid tumors

2026-525948-15-00Advanced Cancer

DrugsAVZO-021·Letrozole·Fulvestrant

Avenzo Therapeutics Inc.

Neoplasms

Spain, France, Germany, Belgium

28/10/2026

Phase I/II

A Phase Ib/II, open-label, safety and tolerability trial of intravenous obrixtamig in combination with pumitamig and standard of care (carboplatin, etoposide) in patients with extensive stage small cell lung carcinoma.

2026-525459-99-00Small cell lung carcinoma

DrugsObrixtamig·Pumitamig·Tocilizumab·Carboplatin

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Germany, Spain, France, Poland, Belgium, Netherlands

26/10/2026

Phase I/II

A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

2026-525614-57-00Advanced Cancer

DrugPembrolizumab

Arvinas Operations Inc.

Neoplasms

Spain, France

22/10/2026

Phase I/II

Phase I/II Clinical Study to Assess the Safety, Efficacy and Select the Dose of NFL-102 as a Tobacco and Nicotine Cessation Therapy (TONIC trial)

2026-527266-77-00Tobacco dependence

Nfl Biosciences

Mental Disorders

France

20/10/2026

Phase I/II

A Double-blind, Randomized, Controlled, Multiple Ascending Dose Study of Intrathecally Administered CMP-002 in Participants with SYNGAP1-Related Disorder (ASCEND)

2026-526220-46-00SYNGAP1-Related Disorder

Camp4 Therapeutics Corp.

Nervous System Diseases

France, Spain, Italy, Netherlands, Poland, Germany

20/10/2026

Phase I/II

A first-in-human phase 1/2 trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of SOT109 in patients with advanced unresectable or metastatic colorectal cancer

2026-526235-19-00Advanced unresectable or metastatic colorectal cancer

SOTIO Biotech a.s.

Neoplasms

Czechia, Spain, France, Belgium

20/10/2026

Phase I/II

A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

2025-523122-40-00EGFR-mutant Non–Small Cell Lung Cancer (NSCLC)

Voronoi Inc.

Neoplasms

France, Poland, Spain

19/10/2026

Phase I/II

Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of VSA012 Injection in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Naïve or Have Not Received Complement Inhibitor Therapy Recently, as well as in Those with Persistent Anemia Despite Stable C5 Complement Inhibitor Therapy

2026-526187-21-00Paroxysmal nocturnal hemoglobinuria (PNH)

DrugVSA012

Bisirna Therapeutics Pte. Ltd.

Hemic and Lymphatic Diseases

Spain, Germany, Italy, France

15/10/2026

Phase I/II

First-in-human study of ATX-898 as monotherapy and in combination with other anti-neoplastic agents, in participants with advanced solid tumors

2026-526514-85-00Advanced solid tumors

DrugsRibociclib·Abemaciclib·Fulvestrant

Antares Therapeutics Inc.

Neoplasms

Netherlands, Spain, France, Italy

05/10/2026

Phase I/II

A Phase Ib/II, open-label, safety and tolerability trial of obrixtamig in combination with ZL-1310 in patients with poorly differentiated NEC

2026-525634-27-00Extrapulmonary neuroendocrine carcinoma of large cell histo…

DrugsZL-1310·Obrixtamig·Tocilizumab·Atezolizumab

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Poland, France, Belgium, Germany, Netherlands, Spain

05/10/2026

Phase I/II

A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements

2026-526409-14-00Acute Myeloid Leukemia

DrugsPosaconazole·Daunorubicin·Cytarabine·Azacitidine

Charm Therapeutics Limited

Neoplasms

France, Germany, Spain, Poland, Netherlands

30/09/2026

Phase I/II

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)

2026-527163-15-00Advanced Renal Cell Carcinoma

DrugsCabozantinib·Ipilimumab

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Ireland, Romania, Italy, Spain, Czechia, Finland, France, Germany

24/09/2026

Phase I/II

An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability.

2026-525698-38-00Hearing Loss Related to biallelic pathogenic variation (s) …

Sensorion

Otorhinolaryngologic Diseases

France

31/08/2026

Phase I/II

A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies

2025-525128-88-00Patients with Acute Myeloid Leukemia (AML), Myelodysplastic…

DrugPosaconazole

Institut De Recherches Internationales Servier IRIS

Neoplasms

Netherlands, Spain, Germany, Italy, France, Finland

27/08/2026

Phase I/II

Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA

2026-525463-40-00osteosarcomas, chondrosarcomas, Ewing sarcomas, Ewing-like …

DrugsDinutuximab beta·Sirolimus·Irinotecan

Les Hopitaux Universitaires De Strasbourg

Neoplasms

France

20/08/2026

Phase I/II

A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

2025-525036-34-00Solid Tumours

DrugsImlunestrant·Fulvestrant

Terremoto Biosciences Inc.

Neoplasms

Spain, Ireland, Hungary, Romania, France, Portugal, Belgium, Poland

18/08/2026

Phase I/II

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)

2025-524915-36-00Lymphoma, Non-Hodgkin

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Germany, Spain, Finland, France

17/08/2026

Phase I/II

A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3

2025-525111-17-00Spinocerebellar ataxia type 3

Institut De Recherches Internationales Servier IRIS

Nervous System Diseases

France, Denmark, Spain, Portugal

30/07/2026

Phase I/II

A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC

2025-524418-27-00Advanced ALK-positive NSCLC

Triana Biomedicines Inc.

Respiratory Tract Diseases

France, Italy, Germany, Spain

22/07/2026

Phase I/II

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

2025-523874-17-00Neoplasms, Prostate

Glaxosmithkline Research & Development Limited

Neoplasms

Netherlands, France, Spain

21/07/2026

Phase I/II

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

2025-525105-20-00Multiple Myeloma (MM), Multiple Myeloma (MM)

DrugEtentamig

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Germany, Poland, Czechia, Belgium, France, Greece, Sweden, Portugal, Italy

13/07/2026

Phase I/II

A PHASE 1/2 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFECTS ON CLINICAL OUTCOMES OF PEGTIBATINASE (TVT-058) ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH CYSTATHIONINE BETASYNTHASE-DEFICIENT HOMOCYSTINURIA (COMPOSE)

2023-509074-31-00Classical Homocystinuria

DrugPegtibatinase

Travere Therapeutics Inc.

Nutritional and Metabolic Diseases

France

07/07/2026

Phase I/II

A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors

2026-525629-20-00Solid tumors

Larkspur Biosciences Inc.

Neoplasms

France

03/07/2026

Phase I/II

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

2025-523438-24-00DLL3 Expressing Tumors Including Small Cell Lung Cancer

DrugDurvalumab

Ideaya Biosciences Inc.

Neoplasms

France, Spain

01/07/2026

Phase I/II

A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

2025-522723-98-00solid tumor

Krystal Biotech Inc.

Neoplasms

France, Spain

30/06/2026

Phase I/II

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome

2025-523835-20-00Dravet Syndrome

Ionis Pharmaceuticals Inc.

Nervous System Diseases

Spain, France, Belgium, Portugal, Germany

30/06/2026

Phase I/II

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors

2025-524623-50-00Solid Tumors

DrugsElironrasib·RMC-9805·Erbitux·Ivonescimab

Revolution Medicines Inc.

Neoplasms

France, Poland, Ireland, Spain, Greece, Germany, Italy, Sweden, Belgium

29/06/2026

Phase I/II

Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy

2026-526324-48-00HCC – Hepatocellular Carcinoma

Centr Georges Francois Leclerc

Neoplasms

France

22/06/2026

Phase I/II

Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product

2024-514190-21-00Ornithine Transcarbamylase Deficiency (OTC)

Iecure Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, France, Slovenia

18/06/2026

Phase I/II

ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

2025-524728-22-01Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Assistance Publique Hopitaux De Paris

Not possible to specify

France

10/06/2026

Phase I/II

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors

2025-523432-39-01Advanced KRAS G12D-Mutant Solid Tumors

Verastem Inc.

Neoplasms

Italy, France, Germany, Belgium, Spain, Netherlands

09/06/2026

Phase I/II

A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer

2025-521032-11-00Small cell lung cancer extensive stage

Merck Sharp & Dohme LLC

Neoplasms

Germany, Poland, Greece, Italy, France, Spain

08/06/2026

Phase I/II

KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments

2025-523537-26-00Locally advanced or metastatic KRAS G12C-mutated non-small …

Novartis Pharma AG

Neoplasms

Spain, Italy, France, Denmark, Belgium

08/06/2026

Phase I/II

REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.

2025-524232-20-00Patients with poor prognostic ovarian cancers based on the …

DrugsUbamatamab·Filgrastim·Paclitaxel·Bevacizumab

Asso De Recherche Cancers Gynecologiques

Neoplasms

France

04/06/2026

Phase I/II

A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.

2025-523590-42-00Locally Advanced or Metastatic Solid Tumors

Crescent Biopharma Inc.

Neoplasms

Spain, Ireland, Italy, France, Romania

02/06/2026

Phase I/II

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma

2025-523005-15-00Non-Hodgkin Lymphoma

Merck Sharp & Dohme LLC

Neoplasms

Poland, Italy, France, Germany, Spain

28/05/2026

Phase I/II

A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC

2025-523276-23-00Extensive stage small cell lung cancer

DrugsBendamustine·Tocilizumab·Fludarabine·Cyclophosphamide

Novartis Pharma AG

Neoplasms

Spain, France

27/05/2026

Phase I/II

Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas

2025-523997-18-00Sarcoma

Glaxosmithkline Research & Development Limited

Neoplasms

France

27/05/2026

Phase I/II

LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

2025-522339-32-00Neoplasm malignant

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Neoplasms

France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia

26/05/2026

Phase I/II

A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours

2025-524620-22-00Neoplasms benign malignant and unspecified (incl. cysts and…

DrugsODM-212·Sotorasib·Ipilimumab·Nivolumab

Orion Corporation

Neoplasms

Finland, Denmark, Spain, France

22/05/2026

Phase I/II

mRNA Therapy to restore lymphatic flow in secondary lymphedema

2024-520149-22-00Lymphedema

Centre Hospitalier Universitaire De Toulouse

Hemic and Lymphatic Diseases

France

18/05/2026

Phase I/II

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

2026-525248-13-00Advanced Solid Tumors

Eikon Therapeutics Inc.

Neoplasms

France, Spain, Norway, Italy, Germany, Austria, Poland, Finland, Belgium, Denmark, Portugal

15/05/2026

Phase I/II

Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN

2024-517130-17-00FLT3-mutated Acute Myeloid Leukemia

DrugVenetoclax

Centre Hospitalier Universitaire De Bordeaux

Neoplasms

France

13/05/2026

Phase I/II

A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies

2025-523399-22-00Advanced Solid Tumours, Melanoma, Clear-Cell Renal-Cell Car…

DrugsREGN10597·Cemiplimab

Regeneron Pharmaceuticals Inc.

Neoplasms

Italy, Spain, Germany, France

08/05/2026

Phase I/II

A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

2025-522019-40-00relapsed or refractory BCR::ABL1-positive (Philadelphia pos…

DrugsAsciminib·Hydrocortisone·Blinatumomab·Cytarabine

Novartis Pharma AG

Neoplasms

Italy, Spain, Germany, Netherlands, France, Denmark, Czechia

27/04/2026

Phase I/II

A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies

2025-523774-16-00Advanced malignancies

DrugsPM54·Pembrolizumab

Pharma Mar S.A.

Neoplasms

Spain, France, Italy

24/04/2026

Phase I/II

COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients

2025-524759-29-00Vulvar Squamous Cell Carcinoma (VSCC) patients

Centre Leon Berard

Female Urogenital Diseases and Pregnancy Complications

France

22/04/2026

Phase I/II

ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

2025-523602-33-00Advanced or unresectable Hepatocellular Carcinoma (HCC)

DrugIpilimumab

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Poland, Spain, Germany, France, Italy

22/04/2026

Phase I/II

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

2025-523474-16-00Malignancies with Documented KRAS, BRAF and Other Selected …

Institut De Recherches Internationales Servier IRIS

Neoplasms

France, Spain, Denmark, Italy

21/04/2026

Phase I/II

Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases

2025-523630-59-00colon carcinoma metastases

HepaRegeniX GmbH

Neoplasms

France, Spain, Germany

20/04/2026

Phase I/II

An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors

2025-521911-38-00Advanced HR+/HER- breast cancer

DrugsLeuprorelin acetate·Goserelin·Letrozole·Fulvestrant

Novartis Pharma AG

Neoplasms

Italy, Germany, France, Czechia, Denmark, Spain

16/04/2026

Phase I/II

A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

2025-522318-21-00Neoplasms, Colorectal

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Denmark, Spain, Sweden, Netherlands, France

14/04/2026

Phase I/II

C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors

2025-523526-40-00Advanced Solid Tumors

Pfizer Inc.

Neoplasms

Italy, Spain, France, Germany

09/04/2026

Phase I/II

C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

2025-523525-17-00Unresectable Locally Advanced or Metastatic Hepatocellular …

DrugsPF-08634404·Ipilimumab

Pfizer Inc.

Neoplasms

Spain, Italy, Germany, France

09/04/2026

Phase I/II

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)

2024-519786-22-01metastatic non-small cell lung cancer (NSCLC)

DrugsRamucirumab·Rilvegostomig

AstraZeneca AB

Neoplasms

Germany, Spain, France, Poland, Belgium, Netherlands, Italy

30/03/2026

Phase I/II

A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors

2025-524010-28-00Advanced Solid Tumor

Repertoire Immune Medicines Inc.

Neoplasms

Spain, Ireland, Portugal, France

17/03/2026

Phase I/II

A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Other Anti-Cancer Therapies in Patients with Advanced Solid Tumors

2025-523742-27-00Advanced solid tumors

Medilink Therapeutics (Suzhou) Co. Ltd.

Neoplasms

Poland, Spain, France, Romania, Italy, Belgium, Hungary, Germany

17/03/2026

Phase I/II

IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO)

2025-524834-24-00diabetic patients pancreatic transplant

Centre Hospitalier Universitaire De Nantes

Immune System Diseases

France

12/03/2026

Phase I/II

An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

2025-523802-34-00Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thromb…

TargED Biopharmaceuticals B.V.

Hemic and Lymphatic Diseases

Germany, France, Italy, Spain

06/03/2026

Phase I/II

A Phase 1/2a Study of REGN7041 (anti-CD3 monoclonal antibody) in patients with Active Noninfectious Uveitis affecting the Posterior Segment

2025-521713-57-00Noninfectious Uveitis

Regeneron Pharmaceuticals Inc.

Eye Diseases

France

05/03/2026

Phase I/II

A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)

2025-521859-23-00PSMA-positive mCRPC with prior exposure to at least one pri…

Novartis Pharma AG

Neoplasms

Germany, France, Spain, Italy

05/03/2026

Phase I/II

A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer)

2025-522944-41-00Solid Tumours

DrugNivolumab

Pathios Therapeutics Limited

Not possible to specify

France, Spain

27/02/2026

Phase I/II

A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer

2024-520238-31-01Advanced Lung Cancer

BioNTech SE

Neoplasms

Spain, France, Italy, Poland

24/02/2026

Phase I/II

A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

2022-502911-12-00Propionic Acidemia

Moderna Inc.

Nutritional and Metabolic Diseases

Spain, Netherlands, France

23/02/2026

Phase I/II

A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults with Chronic Hepatitis B

2025-523619-12-00Chronic Hepatitis B

Nchroma Bio Inc.

Virus Diseases

France

20/02/2026

Phase I/II

A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours

2025-521164-36-00Patients with relapsed/refractory advanced/metastatic ovari…

Apmonia Therapeutics

Neoplasms

Belgium, France

19/02/2026

Phase I/II

Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease

2024-519412-13-00Canavan Disease, Canavan disease

Myrtelle Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

France

18/02/2026

Phase I/II

A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.

2025-522595-87-00Hematological Malignancies

Daiichi Sankyo Inc.

Neoplasms

France, Italy

16/02/2026

Phase I/II

A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)

2025-521671-31-00Relapsed/Refractory (R/R) and Minimal Residual Disease Posi…

Amgen Inc.

Neoplasms

France, Netherlands, Italy

13/02/2026

Phase I/II

A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants with Invasive Ventilator-dependent X-linked Myotubular Myopathy

2025-523213-29-00X-linked myotubular myopathy

DrugASP2957

Astellas Gene Therapies Inc.

Musculoskeletal Diseases

France

09/02/2026

Phase I/II

A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease

2024-519881-32-00Sickle Cell Disease

Novo Nordisk A/S

Hemic and Lymphatic Diseases

France

06/02/2026

Phase I/II

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04–Substudy 04D

2025-522253-19-00Urothelial carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Netherlands, France, Spain

03/02/2026

Phase I/II

Evaluation of a [68Ga] Ga-HER2 single domain antibody PET/CT for predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in HER2-positive early breast cancer

2025-523286-23-00Breast Cancer

Centre Henri Becquerel

Not possible to specify

France

26/01/2026

Phase I/II

A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME

2025-521973-16-00Netherton Syndrome

Biocryst Pharmaceuticals Inc.

Skin and Connective Tissue Diseases

France, Netherlands, Germany

20/01/2026

Phase I/II

DREPAMIR - A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains autologous CD34+ cells transduced ex vivo by the bifunctional βAS3m/miR7m lentiviral vector expressing the βAS3m and a micro-RNA (miRNA) targeting specifically the endogenous βS-globin mRNA in Patients with Sickle Cell Disease (SCD)

2025-521257-17-00SCD severe patients

Assistance Publique Hopitaux De Paris

Hemic and Lymphatic Diseases

France

16/01/2026

Phase I/II

A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer

2025-523273-41-00Metastatic castration-resistant prostate cancer

T.O.A.D. Oncology S.A.

Neoplasms

Spain, France

16/01/2026

Phase I/II

A Phase 1/2, multicentre, open-label clinical trial of DT-7012 as monotherapy and in combination with an immune checkpoint inhibitor in participants with selected advanced solid tumours

2025-523758-15-00Cancer

Domain Therapeutics Australia Pty Limited

Neoplasms

France

14/01/2026

Phase I/II

An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants with Locally Advanced or Metastatic Solid Tumours.

2025-522139-33-00Advanced or metastatic solid tumours

Ipsen Pharma

Neoplasms

France, Spain

23/12/2025

Phase I/II

Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer

2025-520467-40-00High-risk non-muscle invasive bladder cancer (NMIBC) with c…

DrugMK-3120

Merck Sharp & Dohme LLC

Neoplasms

Belgium, Greece, Austria, Spain, Norway, Netherlands, Italy, France

22/12/2025

Phase I/II

TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer

2025-521873-15-00Metastatic hormone-sensitive prostate cancer

Novartis Pharma AG

Neoplasms

Hungary, Spain, Italy, Germany, France

18/12/2025

Phase I/II

An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies

2025-522184-15-00Advanced Solid Tumor, Metastatic Solid Tumor

Ipsen Pharma

Neoplasms

Spain, France

16/12/2025

Phase I/II

TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer

2025-521880-10-00Metastatic castrate resistant prostate cancer (mCRPC)

Novartis Pharma AG

Neoplasms

Italy, Germany, Poland, France, Denmark, Spain

01/12/2025

Phase I/II

InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2 part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN 6400 in Adult Patients with Hereditary Hemorrhagic Telangiectasia (HHT)

2025-522510-23-00Hereditary Hemorrhagic Telangiectasia (HHT)

Alnylam Pharmaceuticals Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

France, Spain, Germany

26/11/2025

Phase I/II

A Phase Ib/ II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Have Previously Progressed During or After a CDK4/6 Inhibitor

2025-521128-31-00Locally Advanced or Metastatic Estrogen Receptor-Positive, …

Genentech Inc.

Neoplasms

Spain, Italy, France, Germany

26/11/2025

Phase I/II

A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

2025-521672-60-00Metastatic or locally advanced SST2-positive neuroendocrine…

Crinetics Pharmaceuticals Inc.

Neoplasms

Spain, France, Germany, Italy

21/11/2025

Phase I/II

Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors

2025-521828-30-00Advanced Solid Tumors

Pyxis Oncology Inc.

Neoplasms

France, Spain, Poland

19/11/2025

Phase I/II

A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors

2025-521441-24-00Advanced or Metastatic Solid Tumors

Alentis Therapeutics AG

Neoplasms

Spain, France, Netherlands, Italy

12/11/2025

Phase I/II

A Phase I/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, and pharmacokinetics of BNT323 in combination with BNT327 in participants with advanced breast cancer

2024-517979-20-00Advanced Breast Cancer Metastatic Breast Cancer

BioNTech SE

Neoplasms

Italy, Spain, France

11/11/2025

Phase I/II

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)

2025-521581-10-00Neoplasms, Prostate

Glaxosmithkline Research & Development Limited

Neoplasms

France, Spain

03/11/2025

Phase I/II

A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)

2025-522517-35-00Patients with advanced/metastatic tumors with head and neck…

Gilead Sciences Inc.

Neoplasms

France, Spain, Romania

03/11/2025

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-europe/country/france

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,788 trial records at the last sync on 08 Nov 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 93 of those trials with a site in France that also match the filters currently applied.

How many recently authorised EU trials have a site in France?

93 of the 2,557 most recently authorised trials in this register list a site in France and match the filters applied; 0 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (France), 93 trials
Phase	Trials	Share
Phase I/II	93	100%

Most active sponsors

Lead sponsors with the most trials (France)
Lead sponsor	Trials
Novartis Pharma AG	7
Glaxosmithkline Research & Development Limited	5
Merck Sharp & Dohme LLC	5
Institut De Recherches Internationales Servier IRIS	3
Assistance Publique Hopitaux De Paris	2
Astellas Gene Therapies Inc.	2
BioNTech SE	2
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.	2
Bristol-Myers Squibb Services Unlimited Company	2
Ipsen Pharma	2

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.